FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175639850> ?p ?o ?g. }

• W3175639850 endingPage "1033" @default.
• W3175639850 startingPage "1026" @default.
• W3175639850 abstract "•We validated the use of corticosteroids for patients with severe alcohol-associated hepatitis defined by an MELD score >20. •The use of corticosteroids was associated with increased 30-day survival. •The maximum benefit of corticosteroids was seen in patients with MELD scores between 25-39. •A MELD score >51 can be used to define futility of corticosteroid treatment in patients with severe AH. •The survival benefit was not sustained at 90 or 180 days. Background & Aims Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH. Methods We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method. Results In our cohort, median age was 49 (40–56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19–29). Survival was 88% (87–89) at 30 days, 77% (76–78) at 90 days, and 72% (72–74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47–0.74; p <0.001). Steroids only improved survival in patients with MELD scores between 21 (HR 0.61; 0.39–0.95; p = 0.027) and 51 (HR 0.72; 0.52–0.99; p = 0.041). The maximum effect of corticosteroid treatment (21–30% survival benefit) was observed with MELD scores between 25 (HR 0.58; 0.42–0.77; p <0.001) and 39 (HR 0.57; 0.41–0.79; p <0.001). No corticosteroid benefit was seen in patients with MELD >51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247). Conclusion Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39. Lay summary Alcohol-associated hepatitis is a condition where the liver is severely inflamed as a result of excess alcohol use. It is associated with high mortality and it is not clear whether the most commonly used treatments (corticosteroids) are effective, particularly in patients with very severe liver disease. In this worldwide study, the use of corticosteroids was associated with increased 30-day, but not 90- or 180-day, survival. The maximal benefit was observed in patients with an MELD score (a marker of severity of liver disease; higher scores signify worse disease) between 25-39. However, this benefit was lost in patients with the most severe liver disease (MELD score higher than 51). Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH. We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method. In our cohort, median age was 49 (40–56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19–29). Survival was 88% (87–89) at 30 days, 77% (76–78) at 90 days, and 72% (72–74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47–0.74; p <0.001). Steroids only improved survival in patients with MELD scores between 21 (HR 0.61; 0.39–0.95; p = 0.027) and 51 (HR 0.72; 0.52–0.99; p = 0.041). The maximum effect of corticosteroid treatment (21–30% survival benefit) was observed with MELD scores between 25 (HR 0.58; 0.42–0.77; p <0.001) and 39 (HR 0.57; 0.41–0.79; p <0.001). No corticosteroid benefit was seen in patients with MELD >51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247). Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39." @default.
• W3175639850 created "2021-07-05" @default.
• W3175639850 creator A5000461392 @default.
• W3175639850 creator A5000641593 @default.
• W3175639850 creator A5002204852 @default.
• W3175639850 creator A5003479866 @default.
• W3175639850 creator A5007361658 @default.
• W3175639850 creator A5008291224 @default.
• W3175639850 creator A5008842913 @default.
• W3175639850 creator A5009002355 @default.
• W3175639850 creator A5010378927 @default.
• W3175639850 creator A5012239800 @default.
• W3175639850 creator A5013247355 @default.
• W3175639850 creator A5013440567 @default.
• W3175639850 creator A5017548534 @default.
• W3175639850 creator A5018974631 @default.
• W3175639850 creator A5019106732 @default.
• W3175639850 creator A5019305946 @default.
• W3175639850 creator A5019669804 @default.
• W3175639850 creator A5022632079 @default.
• W3175639850 creator A5022673296 @default.
• W3175639850 creator A5023015655 @default.
• W3175639850 creator A5026415059 @default.
• W3175639850 creator A5028957654 @default.
• W3175639850 creator A5029239564 @default.
• W3175639850 creator A5029428401 @default.
• W3175639850 creator A5030197466 @default.
• W3175639850 creator A5030206842 @default.
• W3175639850 creator A5032668290 @default.
• W3175639850 creator A5033171011 @default.
• W3175639850 creator A5033243852 @default.
• W3175639850 creator A5034269872 @default.
• W3175639850 creator A5034682808 @default.
• W3175639850 creator A5034965596 @default.
• W3175639850 creator A5035086772 @default.
• W3175639850 creator A5037233298 @default.
• W3175639850 creator A5038516591 @default.
• W3175639850 creator A5039490903 @default.
• W3175639850 creator A5039711392 @default.
• W3175639850 creator A5040861714 @default.
• W3175639850 creator A5041946914 @default.
• W3175639850 creator A5042518181 @default.
• W3175639850 creator A5044025407 @default.
• W3175639850 creator A5046051897 @default.
• W3175639850 creator A5046565205 @default.
• W3175639850 creator A5048615239 @default.
• W3175639850 creator A5048813282 @default.
• W3175639850 creator A5049575058 @default.
• W3175639850 creator A5051150329 @default.
• W3175639850 creator A5052009847 @default.
• W3175639850 creator A5052604947 @default.
• W3175639850 creator A5053100521 @default.
• W3175639850 creator A5053121666 @default.
• W3175639850 creator A5053342076 @default.
• W3175639850 creator A5054101363 @default.
• W3175639850 creator A5055368865 @default.
• W3175639850 creator A5056151137 @default.
• W3175639850 creator A5056562108 @default.
• W3175639850 creator A5056754182 @default.
• W3175639850 creator A5057159694 @default.
• W3175639850 creator A5058490197 @default.
• W3175639850 creator A5059545632 @default.
• W3175639850 creator A5060115347 @default.
• W3175639850 creator A5061895083 @default.
• W3175639850 creator A5061956777 @default.
• W3175639850 creator A5062210742 @default.
• W3175639850 creator A5064816861 @default.
• W3175639850 creator A5064936548 @default.
• W3175639850 creator A5070670112 @default.
• W3175639850 creator A5072936691 @default.
• W3175639850 creator A5074086352 @default.
• W3175639850 creator A5075687052 @default.
• W3175639850 creator A5076699095 @default.
• W3175639850 creator A5078805238 @default.
• W3175639850 creator A5079153438 @default.
• W3175639850 creator A5079791399 @default.
• W3175639850 creator A5080007807 @default.
• W3175639850 creator A5082766478 @default.
• W3175639850 creator A5085194045 @default.
• W3175639850 creator A5086080438 @default.
• W3175639850 creator A5087206886 @default.
• W3175639850 creator A5087509856 @default.
• W3175639850 creator A5088159757 @default.
• W3175639850 creator A5088523363 @default.
• W3175639850 creator A5090321874 @default.
• W3175639850 creator A5091130570 @default.
• W3175639850 date "2021-11-01" @default.
• W3175639850 modified "2023-10-18" @default.
• W3175639850 title "Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study" @default.
• W3175639850 cites W1533012305 @default.
• W3175639850 cites W1558001597 @default.
• W3175639850 cites W1889183644 @default.
• W3175639850 cites W1951722531 @default.
• W3175639850 cites W1987296974 @default.
• W3175639850 cites W2002221121 @default.
• W3175639850 cites W2004073357 @default.
• W3175639850 cites W2033054063 @default.
• W3175639850 cites W2044914971 @default.

• next